Cargando…
PET technology for drug development in psychiatry
Positron emission tomography (PET) is a non‐invasive imaging method to measure the molecule in vivo. PET imaging can evaluate the central nervous system drugs as target engagement in the human brain. For antipsychotic drugs, adequate dopamine D2 receptor occupancy (“therapeutic window”) is reported...
Autores principales: | Arakawa, Ryosuke, Takano, Akihiro, Halldin, Christer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722687/ https://www.ncbi.nlm.nih.gov/pubmed/32463584 http://dx.doi.org/10.1002/npr2.12084 |
Ejemplares similares
-
Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography
por: Arakawa, Ryosuke, et al.
Publicado: (2018) -
Microsome Mediated
in Vitro Metabolism: A Convenient
Method for the Preparation of the PET Radioligand Metabolite [(18)F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
por: Schou, Magnus, et al.
Publicado: (2023) -
Test-retest reproducibility of [(11)C]-l-deprenyl-D(2) binding to MAO-B in the human brain
por: Arakawa, Ryosuke, et al.
Publicado: (2017) -
Guidelines to PET measurements of the target occupancy in the brain for drug development
por: Takano, Akihiro, et al.
Publicado: (2016) -
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [(18)F]FMeNER-D(2)
por: Arakawa, Ryosuke, et al.
Publicado: (2019)